Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Advanced HCC (HCV+ and HCV-)
NCT02940496Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Tolerability of intravenous administration of pembrolizumab and Sustained Virologic Response 12 weeks after end of therapy. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02940496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940496.